Gilead Sciences (GILD) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GILD Analyst Ratings

Strong Buy

19 Buy

4 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

CHF128.81

▲(20.59% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is CHF128.81 with a high forecast of CHF145.56 and a low forecast of CHF97.04. The average price target represents a 20.59% change from the last price of CHF106.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"CHF64","105":"CHF105","146":"CHF146","84.5":"CHF84.5","125.5":"CHF125.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145.5641748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF145.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128.81274198571427,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF128.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.0427832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF97.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,84.5,105,125.5,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.98,108.1018596,111.2237192,114.3455788,117.46743839999999,120.589298,123.71115759999999,126.8330172,129.9548768,133.0767364,136.19859599999998,139.3204556,142.4423152,{"y":145.5641748,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.98,106.81328784505494,108.64657569010988,110.47986353516484,112.31315138021978,114.14643922527472,115.97972707032966,117.81301491538461,119.64630276043955,121.4795906054945,123.31287845054943,125.14616629560439,126.97945414065933,{"y":128.81274198571427,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.98,104.36944486153847,103.75888972307693,103.14833458461538,102.53777944615385,101.92722430769231,101.31666916923078,100.70611403076923,100.0955588923077,99.48500375384616,98.87444861538462,98.26389347692307,97.65333833846154,{"y":97.0427832,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.813,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.813,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.428,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.428,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.428,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.048,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.048,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.492,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.193,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.573,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.944,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF145.56

Average Price TargetCHF128.81

Lowest Price TargetCHF97.04

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tyler Van Buren

TD Cowen

CHF129.39

Buy

21.13%

Upside

Reiterated

08/04/26

Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (NYSE: MD), Certara (NASDAQ: CERT) and Gilead Sciences (NASDAQ: GILD)

Geoff Meacham

Citi

CHF133.43

Buy

24.91%

Upside

Reiterated

08/04/26

Gilead Sciences (GILD) Gets a Buy from Citi

Louise Chen

Scotiabank

CHF143.14

Buy

34.00%

Upside

Reiterated

08/04/26

Gilead Sciences (GILD) Receives a Buy from Scotiabank

Salveen Richter

Goldman Sachs

CHF105.13

Hold

-1.58%

Downside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Danaher (NYSE: DHR) and Henry Schein (NASDAQ: HSIC)

Emily Field

Barclays

CHF117.26

Hold

9.77%

Upside

Reiterated

07/29/26

Gilead Sciences (GILD) Receives a Hold from Barclays

Carter Gould

Cantor Fitzgerald

CHF125.35

Buy

17.34%

Upside

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)

Michael Yee

UBS

CHF141.52

Buy

32.49%

Upside

Reiterated

07/28/26

Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth

Terence Flynn

Morgan Stanley

CHF134.24→CHF133.43

Buy

24.91%

Upside

Reiterated

07/27/26

Gilead price target lowered to $165 from $166 at Morgan StanleyGilead price target lowered to $165 from $166 at Morgan Stanley

Brian Abrahams

RBC Capital

CHF97.04

Hold

-9.15%

Downside

Reiterated

07/23/26

Gilead Sciences (GILD) Gets a Hold from RBC Capital

Evan Seigerman

BMO Capital

CHF140.71

Buy

31.73%

Upside

Assigned

07/23/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Align Tech (NASDAQ: ALGN)

Courtney Breen

Bernstein

CHF129.39

Buy

21.13%

Upside

Reiterated

07/22/26

Analysts' Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)

Daina Graybosch

Leerink Partners

CHF118.07→CHF102.7

Hold

-3.85%

Downside

Downgraded

07/20/26

Gilead downgraded to Market Perform from Outperform at LeerinkGilead downgraded to Market Perform from Outperform at Leerink

Tazeen Ahmad

Bank of America Securities

CHF131.01

Buy

22.64%

Upside

Reiterated

07/13/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)

Mohit Bansal

Wells Fargo

CHF133.43

Buy

24.91%

Upside

Reiterated

07/09/26

Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tyler Van Buren

TD Cowen

CHF129.39

Buy

21.13%

Upside

Reiterated

08/04/26

Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (NYSE: MD), Certara (NASDAQ: CERT) and Gilead Sciences (NASDAQ: GILD)

Geoff Meacham

Citi

CHF133.43

Buy

24.91%

Upside

Reiterated

08/04/26

Gilead Sciences (GILD) Gets a Buy from Citi

Louise Chen

Scotiabank

CHF143.14

Buy

34.00%

Upside

Reiterated

08/04/26

Gilead Sciences (GILD) Receives a Buy from Scotiabank

Salveen Richter

Goldman Sachs

CHF105.13

Hold

-1.58%

Downside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Danaher (NYSE: DHR) and Henry Schein (NASDAQ: HSIC)

Emily Field

Barclays

CHF117.26

Hold

9.77%

Upside

Reiterated

07/29/26

Gilead Sciences (GILD) Receives a Hold from Barclays

Carter Gould

Cantor Fitzgerald

CHF125.35

Buy

17.34%

Upside

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)

Michael Yee

UBS

CHF141.52

Buy

32.49%

Upside

Reiterated

07/28/26

Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth

Terence Flynn

Morgan Stanley

CHF134.24→CHF133.43

Buy

24.91%

Upside

Reiterated

07/27/26

Gilead price target lowered to $165 from $166 at Morgan StanleyGilead price target lowered to $165 from $166 at Morgan Stanley

Brian Abrahams

RBC Capital

CHF97.04

Hold

-9.15%

Downside

Reiterated

07/23/26

Gilead Sciences (GILD) Gets a Hold from RBC Capital

Evan Seigerman

BMO Capital

CHF140.71

Buy

31.73%

Upside

Assigned

07/23/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Align Tech (NASDAQ: ALGN)

Courtney Breen

Bernstein

CHF129.39

Buy

21.13%

Upside

Reiterated

07/22/26

Analysts' Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)

Daina Graybosch

Leerink Partners

CHF118.07→CHF102.7

Hold

-3.85%

Downside

Downgraded

07/20/26

Gilead downgraded to Market Perform from Outperform at LeerinkGilead downgraded to Market Perform from Outperform at Leerink

Tazeen Ahmad

Bank of America Securities

CHF131.01

Buy

22.64%

Upside

Reiterated

07/13/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)

Mohit Bansal

Wells Fargo

CHF133.43

Buy

24.91%

Upside

Reiterated

07/09/26

Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months

Courtney BreenBernstein

Success Rate

15/19 ratings generated profit

Average Return

+6.29%

Copying Courtney Breen's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +6.29% per trade.

1 Year

Courtney BreenBernstein

Success Rate

17/19 ratings generated profit

Average Return

+17.29%

Copying Courtney Breen's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +17.29% per trade.

2 Years

Chris SchottJ.P. Morgan

Success Rate

22/24 ratings generated profit

Average Return

+41.42%

Copying Chris Schott's trades and holding each position for 2 Years would result in 91.67% of your transactions generating a profit, with an average return of +41.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GILD has received 41 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 128.81.

Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is CHF1.74 with a range of CHF1.14 to CHF1.97. The previous quarter’s EPS was -CHF5.46. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is CHF6.29B with a range of CHF6.14B to CHF6.53B. The previous quarter’s sales results were CHF6.31B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is CH:GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 128.81.

What is CH:GILD’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 20.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gilead Sciences a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.

What is Gilead Sciences’s share price target?

The average share price target for Gilead Sciences is 128.81. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF145.56 ,and the lowest forecast is CHF97.04. The average share price target represents 20.59% Increase from the current price of CHF106.82.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Gilead Sciences?

To buy shares of CH:GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Gilead Sciences (GILD) Stock Forecast & Price Target

GILD Analyst Ratings

GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

GILD Analyst Recommendation Trends

GILD Financial Forecast

GILD Earnings Forecast

GILD Sales Forecast

GILD Stock Forecast FAQ

Detailed List of Analyst Forecasts